Reviewing CVRx (NASDAQ:CVRX) and Bluejay Diagnostics (NASDAQ:BJDX)

Bluejay Diagnostics (NASDAQ:BJDX) and CVRx (NASDAQ:CVRX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability and risk.

Profitability

This table compares Bluejay Diagnostics and CVRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bluejay Diagnostics	N/A	-432.21%	-345.69%
CVRx	-92.95%	-84.45%	-42.13%

Institutional and Insider Ownership

18.5% of Bluejay Diagnostics shares are held by institutional investors. Comparatively, 75.3% of CVRx shares are held by institutional investors. 0.1% of Bluejay Diagnostics shares are held by company insiders. Comparatively, 18.9% of CVRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Bluejay Diagnostics and CVRx”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bluejay Diagnostics	$250,000.00	8.54	-$7.72 million	($118.16)	-0.01
CVRx	$51.29 million	4.58	-$59.97 million	($2.02)	-4.44

Bluejay Diagnostics has higher earnings, but lower revenue than CVRx. CVRx is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Bluejay Diagnostics and CVRx, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bluejay Diagnostics	1	0	0	0	1.00
CVRx	2	0	5	1	2.63

CVRx has a consensus target price of $13.17, suggesting a potential upside of 46.95%. Given CVRx’s stronger consensus rating and higher possible upside, analysts clearly believe CVRx is more favorable than Bluejay Diagnostics.

Volatility & Risk

Bluejay Diagnostics has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, CVRx has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500.

Summary

CVRx beats Bluejay Diagnostics on 11 of the 15 factors compared between the two stocks.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.

About CVRx

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.